» Articles » PMID: 24941985

Mdm2 Protein Expression is Strongly Associated with Survival in Malignant Pleural Mesothelioma

Overview
Journal Future Oncol
Specialty Oncology
Date 2014 Jun 20
PMID 24941985
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: TP53 mutations are extremely rare in malignant pleural mesothelioma (MPM). In TP53 wild-type tumors, the functional p53 protein can be inactivated by MDM2.

Materials & Methods: A total of 61 patient samples were tested for their Mdm2 and p53 protein expression levels via immunohistochemistry.

Results: This study demonstrates nuclear Mdm2 expression in three out of four mesothelioma cell lines and 21.3% of the MPM specimens investigated. After silencing of the MDM2 gene by siRNA in MPM cell lines, Mdm2 immunoexpression is lost and cells show changes indicative of severe damage. Mdm2 protein expression in MPM is detected in epithelioid and biphasic subtypes only and is significantly associated with poor survival compared with Mdm2-negative tumors. This may be explained by increased Mdm2 levels possibly leading to an increased ubiquitilation and proteasomal degradation of functional p53 protein.

Conclusion: Expression of Mdm2 is a strong prognostic factor associated with shortened overall survival in MPM.

Citing Articles

Cucurbitacin B Inhibits the Proliferation of WPMY-1 Cells and HPRF Cells via the p53/MDM2 Axis.

Jin Y, Zhou P, Huang S, Shao C, Huang D, Su X Int J Mol Sci. 2024; 25(17).

PMID: 39273281 PMC: 11395236. DOI: 10.3390/ijms25179333.


Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma.

Mairinger E, Wessolly M, Buderath P, Borchert S, Henrich L, Mach P Front Oncol. 2023; 13:1252700.

PMID: 38023247 PMC: 10663300. DOI: 10.3389/fonc.2023.1252700.


Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.

Yang H, Xu D, Schmid R, Peng R Ther Adv Med Oncol. 2020; 12:1758835920971421.

PMID: 33240401 PMC: 7672749. DOI: 10.1177/1758835920971421.


Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.

Yang H, Xu D, Yang Z, Yao F, Zhao H, Schmid R Cancers (Basel). 2020; 12(8).

PMID: 32824422 PMC: 7465812. DOI: 10.3390/cancers12082310.


Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.

Walter R, Sydow S, Berg E, Kollmeier J, Christoph D, Christoph S Cancer Manag Res. 2019; 11:8711-8720.

PMID: 31576173 PMC: 6765394. DOI: 10.2147/CMAR.S194337.